While there was a slight, statistically significant increased prevalence of anti-HERV-K10 Pol peptide antibodies in the LGLL group vs VBD, the more interesting observations were that the HTLV infected population had a statistically significant higher prevalence of antibodies to HERV-K10 Pol peptide than the VBD, and that this prevalence was significantly skewed to those patients with myelopathy. The gene discussed is KRT10; the disease is Myelopathy.